Download PDF
Semin Thromb Hemost 2020; 46(03): 256-263
DOI: 10.1055/s-0040-1708842
Review Article

Thrombocytopenia in Pregnancy: Approach to Diagnosis and Management

Annemarie E. Fogerty
1   Division of Hematology/Oncology, Department of Medicine, Mass General Cancer Center, Massachusetts General Hospital, Boston, Massachusetts
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

The impact of thrombocytopenia varies widely depending on the underlying pathophysiology driving it. The biggest challenge in managing thrombocytopenia in pregnancy is accurately identifying the responsible pathophysiology—a task made difficult given the tremendous overlap in clinical and laboratory abnormalities associated with different thrombocytopenia processes. The most common etiologies of thrombocytopenia in pregnancy range from physiology deemed benign to those that are life-threatening to the mother and fetus. Even in cases in which the responsible etiology is deemed benign, such as gestational thrombocytopenia, there are still implications for the management of labor and delivery, a time where hemostatic challenges may prove life-threatening. In most institutions, a minimum platelet count will be mandated for epidural anesthesia to be deemed a safe option. The causes of thrombocytopenia can also include diagnoses that are pregnancy-specific (such as preeclampsia or gestational thrombocytopenia), potentially triggered by pregnancy (such as thrombotic thrombocytopenic purpura), or unrelated to or predating the pregnancy (such as liver disease, infections, or immune thrombocytopenia purpura). It is imperative that the source of thrombocytopenia is identified accurately and expeditiously, as intervention can range from observation alone to urgent fetal delivery. In this review, the approach to diagnosis and the pathophysiological mechanisms of the most common etiologies of thrombocytopenia in pregnancy and associated management issues are presented.

Keywords

pregnancy - thrombocytopenia - microangiopathy - preeclampsia - TTP


Publication History

Publication Date:
07 April 2020 (online)

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Fogerty AE. Thrombocytopenia in pregnancy: mechanisms and management. Transfus Med Rev 2018; 32 (04) 225-229
    CrossrefPubMedGoogle Scholar
  • 2 McCrae KR. Thrombocytopenia in pregnancy: differential diagnosis, pathogenesis, and management. Blood Rev 2003; 17 (01) 7-14
    CrossrefPubMedGoogle Scholar
  • 3 Zhang X, Zhao Y, Li X. et al. Thrombopoietin: a potential diagnostic indicator of immune thrombocytopenia in pregnancy. Oncotarget 2016; 7 (07) 7489-7496
    CrossrefPubMedGoogle Scholar
  • 4 Freedman J, Musclow E, Garvey B, Abbott D. Unexplained periparturient thrombocytopenia. Am J Hematol 1986; 21 (04) 397-407
    CrossrefPubMedGoogle Scholar
  • 5 Lescale KB, Eddleman KA, Cines DB. et al. Antiplatelet antibody testing in thrombocytopenic pregnant women. Am J ObstetGynecol 1996; 174 (03) 1014-1018
    CrossrefPubMedGoogle Scholar
  • 6 Jodkowska A, Martynowicz H, Kaczmarek-Wdowiak B, Mazur G. Thrombocytopenia in pregnancy - pathogenesis and diagnostic approach. PostepyHig Med Dosw 2015; 69: 1215-1221
    CrossrefPubMedGoogle Scholar
  • 7 Drury-Stewart DN, Lannert KW, Chung DW. et al. Complex changes in von Willebrand factor-associated parameters are acquired during uncomplicated pregnancy. PLoS One 2014; 9 (11) e112935
    CrossrefPubMedGoogle Scholar
  • 8 Sánchez-Luceros A, Farías CE, Amaral MM. et al. von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. ThrombHaemost 2004; 92 (06) 1320-1326
    PubMedGoogle Scholar
  • 9 Lattuada A, Rossi E, Calzarossa C, Candolfi R, Mannucci PM. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 2003; 88 (09) 1029-1034
    PubMedGoogle Scholar
  • 10 Stepanian A, Cohen-Moatti M, Sanglier T. et al; ECLAXIR Study Group. Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology. ArteriosclerThrombVascBiol 2011; 31 (07) 1703-1709
    PubMedGoogle Scholar
  • 11 Aref S, Goda H. Increased VWF antigen levels and decreased ADAMTS13 activity in preeclampsia. Hematology 2013; 18 (04) 237-241
    CrossrefPubMedGoogle Scholar
  • 12 Reese JA, Peck JD, McIntosh JJ, Vesely SK, George JN. Platelet counts in women with normal pregnancies: a systematic review. Am J Hematol 2017; 92 (11) 1224-1232
    CrossrefPubMedGoogle Scholar
  • 13 Reese JA, Peck JD, Deschamps DR. et al. Platelet counts during pregnancy. N Engl J Med 2018; 379 (01) 32-43
    CrossrefPubMedGoogle Scholar
  • 14 Ruggeri M, Schiavotto C, Castaman G, Tosetto A, Rodeghiero F. Gestational thrombocytopenia: a prospective study. Haematologica 1997; 82 (03) 341-342
    PubMedGoogle Scholar
  • 15 Anteby E, Shalev O. Clinical relevance of gestational thrombocytopenia of < 100,000/microliters. Am J Hematol 1994; 47 (02) 118-122
    CrossrefPubMedGoogle Scholar
  • 16 Wang X, Xu Y, Luo W. et al. Thrombocytopenia in pregnancy with different diagnoses: differential clinical features, treatments, and outcomes. Medicine (Baltimore) 2017; 96 (29) e7561
    CrossrefPubMedGoogle Scholar
  • 17 Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J ThrombHaemost 2006; 4 (11) 2377-2383
    CrossrefPubMedGoogle Scholar
  • 18 Stavrou E, McCrae KR. Immune thrombocytopenia in pregnancy. HematolOncolClin North Am 2009; 23 (06) 1299-1316
    CrossrefPubMedGoogle Scholar
  • 19 Provan D, Stasi R, Newland AC. et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115 (02) 168-186
    CrossrefPubMedGoogle Scholar
  • 20 McMillan R, Wang L, Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J ThrombHaemost 2003; 1 (03) 485-491
    CrossrefPubMedGoogle Scholar
  • 21 Khaspekova SG, Shustova ON, Golubeva NV, Naimushin YA, Larina LE, Mazurov AV. Circulating antiplatelet antibodies in pregnant women with immune thrombocytopenic purpura as predictors of thrombocytopenia in the newborns. Platelets 2019; 30 (08) 1008-1012
    CrossrefPubMedGoogle Scholar
  • 22 Webert KE, Mittal R, Sigouin C, Heddle NM, Kelton JG. A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura. Blood 2003; 102 (13) 4306-4311
    CrossrefPubMedGoogle Scholar
  • 23 Veneri D, Franchini M, Raffaelli R. et al. Idiopathic thrombocytopenic purpura in pregnancy: analysis of 43 consecutive cases followed at a single Italian institution. Ann Hematol 2006; 85 (08) 552-554
    CrossrefPubMedGoogle Scholar
  • 24 Sun D, Shehata N, Ye XY. et al. Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy. Blood 2016; 128 (10) 1329-1335
    CrossrefPubMedGoogle Scholar
  • 25 Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ 2011; 183 (07) 796-804
    CrossrefPubMedGoogle Scholar
  • 26 Park-Wyllie L, Mazzotta P, Pastuszak A. et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62 (06) 385-392
    CrossrefPubMedGoogle Scholar
  • 27 Myers B. Diagnosis and management of maternal thrombocytopenia in pregnancy. Br J Haematol 2012; 158 (01) 3-15
    CrossrefPubMedGoogle Scholar
  • 28 Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood 2011; 117 (05) 1499-1506
    CrossrefPubMedGoogle Scholar
  • 29 Purushothaman J, Puthumana KJ, Kumar A, Innah SJ, Gilvaz S. A case of refractory immune thrombocytopenia in pregnancy managed with elthrombopag. Asian J TransfusSci 2016; 10 (02) 155-158
    CrossrefPubMedGoogle Scholar
  • 30 Kong Z, Qin P, Xiao S. et al. A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. Blood 2017; 130 (09) 1097-1103
    CrossrefPubMedGoogle Scholar
  • 31 Milne F, Redman C, Walker J. et al. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. BMJ 2005; 330 (7491): 576-580
    CrossrefPubMedGoogle Scholar
  • 32 American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. ObstetGynecol 2013; 122 (05) 1122-1131
    PubMedGoogle Scholar
  • 33 MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. ObstetGynecol 2001; 97 (04) 533-538
    PubMedGoogle Scholar
  • 34 Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20 (01) IX-XIV
    CrossrefPubMedGoogle Scholar
  • 35 Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J ObstetGynecol 2013; 209 (06) 544.e1-544.e12
    CrossrefPubMedGoogle Scholar
  • 36 Karumanchi SA, Maynard SE, Stillman IE, Epstein FH, Sukhatme VP. Preeclampsia: a renal perspective. Kidney Int 2005; 67 (06) 2101-2113
    CrossrefPubMedGoogle Scholar
  • 37 Keiser SD, Owens MY, Parrish MR. et al. HELLP syndrome with and without eclampsia. Am J Perinatol 2011; 28 (03) 187-194
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Martin Jr JN, Rose CH, Briery CM. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J ObstetGynecol 2006; 195 (04) 914-934
    CrossrefPubMedGoogle Scholar
  • 39 Wallace K, Martin Jr JN, Tam Tam K. et al. Seeking the mechanism(s) of action for corticosteroids in HELLP syndrome: SMASH study. Am J ObstetGynecol 2013; 208 (05) 380.e1-380.e8
    CrossrefPubMedGoogle Scholar
  • 40 Kohli S, Ranjan S, Hoffmann J. et al. Maternal extracellular vesicles and platelets promote preeclampsia via inflammasome activation in trophoblasts. Blood 2016; 128 (17) 2153-2164
    CrossrefPubMedGoogle Scholar
  • 41 Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2019; 2019 (10) DOI: 10.1002/14651858.CD004659.pub3. [epub ahead of print]
    CrossrefPubMedGoogle Scholar
  • 42 Mallampati D, Grobman W, Rouse DJ, Werner EF. Strategies for prescribing aspirin to prevent preeclampsia. ObstetGynecol 2019; 134 (03) 537-544
    PubMedGoogle Scholar
  • 43 Soto E, Romero R, Kusanovic JP. et al. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med 2012; 25 (05) 498-507
    CrossrefPubMedGoogle Scholar
  • 44 Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) 2009; 24: 147-158
    PubMedGoogle Scholar
  • 45 Levine RJ, Maynard SE, Qian C. et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350 (07) 672-683
    CrossrefPubMedGoogle Scholar
  • 46 Verlohren S, Galindo A, Schlembach D. et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J ObstetGynecol 2010; 202 (02) 161.e1-161.e11
    CrossrefPubMedGoogle Scholar
  • 47 Verlohren S, Herraiz I, Lapaire O. et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J ObstetGynecol 2012; 206 (01) 58.e1-58.e8
    CrossrefPubMedGoogle Scholar
  • 48 Villa PM, Hämäläinen E, Mäki A. et al. Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort. BMC Pregnancy Childbirth 2013; 13: 110
    CrossrefPubMedGoogle Scholar
  • 49 Vaught AJ, Gavriilaki E, Hueppchen N. et al. Direct evidence of complement activation in HELLP syndrome: a link to atypical hemolytic uremic syndrome. ExpHematol 2016; 44 (05) 390-398
    PubMedGoogle Scholar
  • 50 Burwick RM, Feinberg BB. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta 2013; 34 (02) 201-203
    CrossrefPubMedGoogle Scholar
  • 51 Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. ObstetGynecol 2004; 103 (5 Pt 1): 981-991
    PubMedGoogle Scholar
  • 52 Nelson DB, Yost NP, Cunningham FG. Acute fatty liver of pregnancy: clinical outcomes and expected duration of recovery. Am J ObstetGynecol 2013; 209 (05) 456.e1-456.e7
    CrossrefPubMedGoogle Scholar
  • 53 Castro MA, Fassett MJ, Reynolds TB, Shaw KJ, Goodwin TM. Reversible peripartum liver failure: a new perspective on the diagnosis, treatment, and cause of acute fatty liver of pregnancy, based on 28 consecutive cases. Am J ObstetGynecol 1999; 181 (02) 389-395
    CrossrefPubMedGoogle Scholar
  • 54 Knight M, Nelson-Piercy C, Kurinczuk JJ, Spark P, Brocklehurst P. UK Obstetric Surveillance System. A prospective national study of acute fatty liver of pregnancy in the UK. Gut 2008; 57 (07) 951-956
    CrossrefPubMedGoogle Scholar
  • 55 Ch'ng CL, Morgan M, Hainsworth I, Kingham JG. Prospective study of liver dysfunction in pregnancy in Southwest Wales. Gut 2002; 51 (06) 876-880
    Google Scholar
  • 56 Bacq Y. Liver diseases unique to pregnancy: a 2010 update. Clin Res HepatolGastroenterol 2011; 35 (03) 182-193
    CrossrefPubMedGoogle Scholar
  • 57 Davidson KM, Simpson LL, Knox TA, D'Alton ME. Acute fatty liver of pregnancy in triplet gestation. ObstetGynecol 1998; 91 (5 Pt 2): 806-808
    PubMedGoogle Scholar
  • 58 Creasy RK, Resnick R, Iams JD, Lockwood CJ, Moore TR. Creasy and Resnick's Maternal-Fetal Medicine: Principles and Practice. 6th ed. Philadelphia, PA: Saunders/Elsevier; 2009
  • 59 Liu J, Ghaziani TT, Wolf JL. Acute fatty liver disease of pregnancy: updates in pathogenesis, diagnosis, and management. Am J Gastroenterol 2017; 112 (06) 838-846
    Google Scholar
  • 60 Chen H, Yuan L, Tan J, Liu Y, Zhang J. Severe liver disease in pregnancy. Int J GynaecolObstet 2008; 101 (03) 277-280
    PubMedGoogle Scholar
  • 61 Scully M. Thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome microangiopathy in pregnancy. SeminThrombHemost 2016; 42 (07) 774-779
    PubMedGoogle Scholar
  • 62 Scully M, Thomas M, Underwood M. et al; collaborators of the UK TTP Registry. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood 2014; 124 (02) 211-219
    CrossrefPubMedGoogle Scholar
  • 63 Vesely SK, Li X, McMinn JR, Terrell DR, George JN. Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2004; 44 (08) 1149-1158
    CrossrefPubMedGoogle Scholar
  • 64 Fakhouri F, Roumenina L, Provot F. et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am SocNephrol 2010; 21 (05) 859-867
    PubMedGoogle Scholar
  • 65 Kelly RJ, Höchsmann B, Szer J. et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2015; 373 (11) 1032-1039
    CrossrefPubMedGoogle Scholar